Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04771130 · ClinicalTrials.gov registry record · Phase 1

A Study of BGB-11417 in Participants With Myeloid Malignancies

A Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, sponsored by BeiGene.

Recruiting
Registry status
Phase 1
Development phase
260
Enrollment target
20
Study locations

NCT04771130 is a Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes that is actively recruiting participants, run by BeiGene. The registered enrollment target is 260 participants, above the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (126% higher). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04771130, a Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, is actively recruiting participants, sponsored by BeiGene.

RECRUITING
Registry status
Phase 1
Development phase
260 participants
Enrollment target
20
Study locations

Study Summary

The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)or MDS/myeloproliferative neoplasm (MPN) .

Conditions Studied

Acute Myeloid Leukemia Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasm

Interventions

  • DRUG Azacitidine
  • DRUG Posaconazole
  • DRUG BGB-11417

Study Locations (20)

Victoria

  • Monash Health - Clayton
  • St Vincents Hospital Melbourne - Fitzroy
  • Austin Health - Heidelberg
  • The Alfred Hospital - Melbourne

New South Wales

  • Concord Repatriation General Hospital - Concord
  • St George Hospital - Kogarah
  • Orange Health Hospital - Orange

Western Australia

  • Fiona Stanley Hospital - Murdoch
  • Linear Clinical Research - Nedlands
  • One Clinical Research - Nedlands

Guangdong

  • Guangdong Provincial Peoples Hospital - Guangzhou
  • Nanfang Hospital of Southern Medical University - Guangzhou

California

  • City of Hope National Medical Center - Duarte

Florida

  • Tampa General Hospital - Tampa

Pennsylvania

  • Upmc Hillman Cancer Center(Univ of Pittsburgh) - Pittsburgh

Texas

  • Md Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 260 participants
Start Date 2021-05-24
Est. Completion 2028-02-08
Phase Phase 1

Sponsor

BeiGene

65 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04771130

The ClinicalTrials.gov registry entry for NCT04771130 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (126% higher). The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Azacitidine is the first listed.

NCT04771130 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Victoria, New South Wales, Western Australia.

Frequently Asked Questions

What is clinical trial NCT04771130 about?

NCT04771130 is a clinical study titled "A Study of BGB-11417 in Participants With Myeloid Malignancies". The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)or MDS/myeloproliferative neoplasm (MPN) .

What is the current status of trial NCT04771130?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 260 participants. The study started on 2021-05-24. Estimated completion is 2028-02-08.

What conditions does trial NCT04771130 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm.

What interventions are being tested in trial NCT04771130?

The interventions under investigation include: Azacitidine (DRUG), Posaconazole (DRUG), BGB-11417 (DRUG).

Who is sponsoring clinical trial NCT04771130?

This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04771130 being conducted?

This trial has 20 study locations across California, Florida, Pennsylvania, Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Myeloid Leukemia

All registered trials for this condition

Myelodysplastic Syndromes

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.